The Medical Letter on Drugs and Therapeutics
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an extended-release (ER) capsule formulation of amantadine (Gocovri – Adamas) for once-daily treatment of levodopa-induced dyskinesia in patients with Parkinson's disease (PD). It is the first product to be approved in the US for this indication. Immediate-release (IR) amantadine has been used off-label for years to manage levodopa-induced dyskinesia.

LEVODOPA-INDUCED DYSKINESIA — Levodopa combined with carbidopa is still the most effective treatment for symptoms of PD, but motor fluctuations and dyskinesia can be problematic as the disease progresses and higher levodopa doses are needed.1-3 Addition of a dopamine agonist, catechol O-methyltransferase (COMT) inhibitor, or monoamine oxidase type-B (MAO-B) inhibitor can reduce motor fluctuations, but may also increase the risk of dyskinesia. Amantadine can reduce levodopa-induced dyskinesia, and it ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
Article code: 1535c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian